FDA Clears Trial for Dual-Targeted CAR T-Cell Cancer Therapy
Food and Drug Administration this week to test genetically engineered CAR T-cell immune cells in adults with advanced colorectal cancer and pediatric patients with solid tumors, according to university announcements. The experimental therapy attacks two specific targets, B7-H3 and IL-8, aiming to overcome the defenses of solid tumors where standard treatments have failed. University of … Read more